Transforming treatment paradigms for patients with multiple myeloma Our commitment to the blood cancer community is driven and inspired by our mission to reimagine care so patients can redefine living." "At ASH, we look forward to working with the oncology community to advance the understanding and use of novel treatments and address unmet patient needs, with the ultimate goal of developing curative therapies. President, Oncology, Janssen Biotech, Inc. "As evidenced by our presence at ASH, we are continuously pushing boundaries to treat cancer," said Serge Messerlian, U.S.
"We continue to deepen and accelerate our understanding of blood cancers as we strive toward our vision – the elimination of cancer." "We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH 2021," said Peter Lebowitz, M.D., Ph.D., Global Therapeutic Area Head, Oncology, Janssen Research & Development, LLC. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021. 4, 2021 /PRNewswire/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition.
0 kommentar(er)
